Cefepime
- Generic Name
- Cefepime
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N6O5S2
- CAS Number
- 88040-23-7
- Unique Ingredient Identifier
- 807PW4VQE3
- Background
Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, and has greater activity against both compared to third-generation antibiotics. Cefepime is normally used to treat severe nosocomial pneumonia and infections caused by multi-resistant microorganisms such as Pseudomo...
- Indication
Cefepime is indicated for the treatment of pneumonia caused by susceptible bacteria, and for empiric therapy for febrile neutropenic patients. Cefepime is also indicated for the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and complicated intra-abdominal infe...
- Associated Conditions
- Bacterial Infections, Complicated Intra-Abdominal Infections (cIAIs), Complicated Urinary Tract Infection, Febrile Neutropenia, Meningitis, Bacterial, Pyelonephritis, Severe Pneumonia, Uncomplicated Urinary Tract Infections, Moderate Pneumonia, Uncomplicated skin and subcutaneous tissue bacterial infections
- Associated Therapies
- -
Early Antibiotics After Aspiration in ICU Patients
- Conditions
- Interventions
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- UConn Health
- Target Recruit Count
- 5
- Registration Number
- NCT05079620
- Locations
- 🇺🇸
UConn Health, John Dempsey Hospital, Farmington, Connecticut, United States
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04983901
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Antibiotics Continuous Infusion at Home
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Ospedale San Carlo Borromeo
- Target Recruit Count
- 50
- Registration Number
- NCT04816968
- Locations
- 🇮🇹
ASST Santi Paolo Carlo - San Carlo Borromeo Hospital - SSd Onco-Hematology, Milan, Italy
Single Dose Cefepime Versus Cefuroxime Plus Metronidazole as a Prophylactic Antibiotic During Emergency Intrapartum Cesarean Section
- Conditions
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 500
- Registration Number
- NCT04009772
- Locations
- 🇪🇬
Assiut University, Assiut, Egypt
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT03485950
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 347
- Registration Number
- NCT03078010
- Locations
- 🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 154
- Registration Number
- NCT02872038
- Locations
- 🇹🇭
Chulalongkorn University, Bangkok, Thailand
PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 129
- Registration Number
- NCT02820987
- Locations
- 🇫🇷
Chu Besancon, Besançon, France
Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 2
- Registration Number
- NCT02732327
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)
- Conditions
- Interventions
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 97
- Registration Number
- NCT02497781
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇨🇿Lekarna Oblastni nemocnice Kolin, a.s., Kolin III, Czechia
🇺🇸ProMedica Toledo Children's Hospital, Toledo, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.